MESO
MESOBLAST LTDPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 4 to Apr 10 ▲ 3 days of insider buys: $30.0M by 1 insider, avg $1.92
- Apr 10 ▲ Mesoblast received FDA clearance to proceed directly into a registra…
- Jul 14 ▲ Mesoblast announced it has enrolled the target of 300 patients in th…
- Jul 30 ▲ Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and U…
- Aug 17 FDA: Mesoblast Achieves Major Milestone Completing Patient Trea…
- Aug 17 ▲ Mesoblast completed patient treatment in the pivotal Phase 3 trial (…
- Aug 27 ▲ Mesoblast filed its annual 20-F for FY2026, reporting first full-yea…
- Aug 27 ▲ Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2…
- Oct 13 Mesoblast filed its FY2026 annual report (20-F) via a 6-K, reporting…
- Oct 16 ▲ Mesoblast reported a 44% increase in Ryoncil net revenue to $28M for…
- Oct 29 ▲ Mesoblast reported Q1 FY2027 Ryoncil net revenue of $28M, up 44% YoY…
- Oct 29 ▲ Mesoblast reported Q1 FY2027 RYONCIL net revenue of $28M, up 44% YoY…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $30.0M. No open-market sales.
- InstitutionsBULLISH
Q3 2026: 8 added (0 new), 0 trimmed or exited.
- AnalystsBULLISH
9 of 10 rate it Buy or better.
- EstimatesFALLING
Current-quarter EPS estimate $0.080 → −$0.080 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +9.5% to 3.58M shares. 10.2 days to cover, ≈2.8% of shares.
- TrendRANGE
12% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GROUP ONE TRADING LLC | DOUBLED | $1.9M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $442.1K |
| BARCLAYS PLC | ADD | $71.2K |
| OSAIC HOLDINGS, INC. | ADD | $41.0K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | $12.1K |
| Allworth Financial LP | DOUBLED | $3.4K |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | $791.00 |
| MORGAN STANLEY | ADD | $9.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analysts| Date | Firm | Rating |
|---|---|---|
| Aug 27, 2026 | Piper Sandler REITERATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
George Gregory Director Apr 10, 2026 | BUY | $3.4M |
George Gregory Director Apr 10, 2026 | BUY | $3.4M |
George Gregory Director Apr 9, 2026 | BUY | $7.2K |
George Gregory Director Apr 9, 2026 | BUY | $14.1K |
George Gregory Director Apr 9, 2026 | BUY | $7.5K |
George Gregory Director Apr 9, 2026 | BUY | $14.3K |
George Gregory Director Apr 9, 2026 | BUY | $28.6K |
George Gregory Director Apr 9, 2026 | BUY | $6.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.08 | -$0.08–-$0.08 | -200.0% | $54.9M |
| Next Q | -$0.07 | -$0.07–-$0.07 | -187.5% | $57.2M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 6 press releases · 11 bullish · 0 bearish · 2 mixed · 6 neutral- NEUTRAL 6-KNov 16, 2026
Mesoblast filed a Form 6-K reporting the appointment of Jon Voigtman as a new director, effective November 10, 2026. The filing includes an initial directors interest notice disclosing Voigtman's beneficial ownership of 186 American Depositary Shares (representing 1,860 ordinary shares).
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 6-KNov 10, 2026
Mesoblast held its 2026 Annual General Meeting, reporting FY2026 Ryoncil net revenue of $115M…
Monitor the CLBP Phase 3 readout in H2 CY2027 and the adult SR-aGvHD interim analysis in Q4 CY2027 as key catalysts. The LVAD BLA filing timeline and potential cardiopulmonary partnership are also…
- NEUTRAL 6-KNov 2, 2026
Mesoblast announced the retirement of two board members (William Burns and Dr. Philip Krause) and…
Monitor the appointment of new commercial-focused directors as an indicator of execution strategy for Ryoncil's US launch and pipeline advancement. No immediate stock-moving catalyst from this filing.
- BULLISH 6-KOct 29, 2026
Mesoblast reported Q1 FY2027 Ryoncil net revenue of $28M, up 44% YoY, and reduced net operating…
Watch for the Phase 3 CLBP 12-month pain reduction readout next year and the formal FDA meeting minutes for the rexlemestrocel-L BLA filing. Adult SR-aGvHD trial enrollment progress and Ryoncil…
All MESO filing & press-release reports (25)
- 6-K reportNov 16, 2026
- 6-K reportNov 10, 2026
- 6-K reportNov 2, 2026
- 6-K reportOct 29, 2026
- PRESS-RELEASE reportOct 28, 2026
- 6-K reportOct 15, 2026
- 6-K reportOct 15, 2026
- 6-K reportOct 13, 2026
- 6-K reportSep 23, 2026
- 20-F reportAug 27, 2026
- PRESS-RELEASE reportAug 26, 2026
- 6-K reportAug 24, 2026
- PRESS-RELEASE reportAug 16, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 14, 2026
- PRESS-RELEASE reportJul 13, 2026
- 6-K reportJul 9, 2026
- PRESS-RELEASE reportJul 9, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 24, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 28, 2026
- PRESS-RELEASE reportApr 14, 2026
- PRESS-RELEASE reportApr 10, 2026
- PRESS-RELEASE reportApr 8, 2026